RT Journal Article
SR Electronic
T1 The tumor suppressor Adenomatous polyposis coli regulates T lymphocyte migration. Insights from familial polyposis patients
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.06.21.21259262
DO 10.1101/2021.06.21.21259262
A1 Marta Mastrogiovanni
A1 Pablo Vargas
A1 Thierry Rose
A1 Céline Cuche
A1 Marie Juzans
A1 Elric Esposito
A1 Hélène Laude
A1 Charlotte Renaudat
A1 Marie-Noëlle Ungeheuer
A1 Jérôme Delon
A1 Andrés Alcover
A1 Vincenzo Di Bartolo
YR 2021
UL http://medrxiv.org/content/early/2021/06/30/2021.06.21.21259262.abstract
AB Adenomatous polyposis coli (APC) is a tumor suppressor whose mutations underlie familial adenomatous polyposis (FAP) and colorectal cancer. Although its role in intestinal epithelial cells is well characterized, APC importance for anti-tumor immunity is ill defined. APC regulates cytoskeleton organization, cell polarity and migration in various cells types. Here we address whether APC plays a role in T lymphocyte migration, a key step of anti-tumor immune responses.Using a series of cell biology tools, we demonstrated that T cells from FAP patients carrying APC mutations display adhesion and migration defects. Concomitantly, they presented lower expression of the integrin VLA-4. To further dissect the cellular mechanisms underpinning these defects, we depleted APC in the CEM T cell line. We found that APC is critical not only for VLA-4-dependent adhesion but also for actomyosin and microtubule organization in migrating T cells. Finally, APC-silenced CEM cells preferentially adopt an ameboid-like migration featuring unstructured pseudopodia and blebbing.These findings underscore a role of APC in T cell migration via modulation of integrin-dependent adhesion and cytoskeleton reorganization. Hence, APC mutations in FAP patients not only drive intestinal neoplasms, but also impair T cell migration, potentially leading to inefficient T cell-mediated anti-tumor immunity.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by grants from La Ligue Nationale contre le Cancer, Equipe Labelliseée Ligue 2018, and institutional grants from the Institut Pasteur and INSERM. UtechS Photonic BioImaging is supported by the National Research Agency (France BioImaging; ANR_10_INBS_04; Investments for the Future). M.M. is a scholar of the Pasteur Paris University International Doctoral Program, supported by the Institut Pasteur and the European Union Horizon 2020 Research and Innovation Programme under the Marie Sklodowska-Curie grant agreement 665807 (COFUND-PASTEURDOC). MM is currently funded by ‘Allocation doctorales 4ème anneée de thèse-La Ligue Contre Le Cancer’.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:CoSImmGEn protocols approved by the Committee of Protection of Persons, Ile de France-1 (No 2010-dec-12483 for healthy donors and No 2018-mai-14852 for FAP patients)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data will be made available upon request addressed to the corresponding authors.